Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | May 6, 2003 | ||||
Last Updated Date | February 6, 2009 | ||||
Start Date ICMJE | March 2003 | ||||
Current Primary Outcome Measures ICMJE |
Overall survival at 18 months [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE |
Overall survival at 18 months | ||||
Change History | Complete list of historical versions of study NCT00059826 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Descriptive Information | |||||
Brief Title ICMJE | Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer | ||||
Official Title ICMJE | A Phase II Study of Interferon-Based Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma | ||||
Brief Summary | RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Radiation therapy uses high-energy radiation from x-rays and other sources to kill tumor cells. Combining chemotherapy with interferon alfa and giving them with radiation therapy after surgery may kill any remaining tumor cells. PURPOSE: Phase II trial to study the effectiveness of adjuvant chemoradiotherapy and interferon alfa in treating patients who have resected stage I, stage II, or stage III pancreatic cancer. |
||||
Detailed Description | OBJECTIVES:
OUTLINE: This is a multicenter study.
PROJECTED ACCRUAL: A total of 93 patients will be accrued for this study within 2 years. |
||||
Study Phase | Phase II | ||||
Study Type ICMJE | Interventional | ||||
Study Design ICMJE | Treatment, Open Label | ||||
Condition ICMJE | Pancreatic Cancer | ||||
Intervention ICMJE |
|
||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Enrollment ICMJE | |||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria ICMJE | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID ICMJE | NCT00059826 | ||||
Responsible Party | |||||
Study ID Numbers ICMJE | CDR0000298776, ACOSOG-Z05031 | ||||
Study Sponsor ICMJE | American College of Surgeons | ||||
Collaborators ICMJE | National Cancer Institute (NCI) | ||||
Investigators ICMJE |
|
||||
Information Provided By | National Cancer Institute (NCI) | ||||
Verification Date | January 2006 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |